QHSLab, Inc. reported a significant increase in financial performance for the fiscal year ending December 31, 2025, with total revenues reaching $2.69 million, up from $2.13 million in 2024. This 26.2% growth was primarily driven by a 74.3% increase in revenue from Integrated Service Program (ISP) services, which generated $1.12 million, and a 19.2% rise in sales of immunotherapy treatments, totaling $487,762. The company also achieved a net income of $457,417, a notable turnaround from a net loss of $259,239 in the previous year, largely attributed to a gain of $1.15 million from the extinguishment of debt.
Operationally, QHSLab has focused on expanding its digital health platform, which integrates behavioral health management and allergy diagnostics through its QHSLab and AllergiEnd® services. The company has seen an increase in customer engagement, with a growing number of independent primary care practices adopting its services. As of March 30, 2026, QHSLab employed 12 full-time staff members and engaged independent contractors for various operational needs. The company’s strategy includes enhancing its product offerings and increasing patient enrollment per practice, which is expected to drive recurring revenue growth.
In terms of market presence, QHSLab has positioned itself within a competitive landscape that includes various healthcare technology providers. The company aims to leverage the increasing demand for digital health solutions and the ongoing shift towards preventive care and population health management. The integration of allergy diagnostics into its digital platform is expected to enhance patient engagement and revenue per practice over time. The company’s sales strategy targets independent, physician-led primary care practices, which are increasingly seeking to manage chronic conditions traditionally referred to specialists.
Looking ahead, QHSLab's management has expressed optimism about sustaining revenue growth through continued product development and strategic partnerships. However, the company acknowledges the challenges posed by its history of operating losses and the need for additional financing to support its growth initiatives. The management's outlook emphasizes the importance of generating consistent positive cash flow and maintaining operational efficiency to navigate the evolving healthcare landscape.
About QHSLab, Inc.
QHSLab, Inc. develops digital healthcare software and SaaS solutions for primary care providers, focusing on chronic disease management, preventive care, and digital medicine. Its platforms, including QHSLab and AllergiEnd, enable remote monitoring, diagnostics, and targeted allergen immunotherapy, enhancing practice revenues and patient outcomes. The company operates in a highly regulated industry, competing with larger firms, and emphasizes value-based, patient-centered, and cost-effective healthcare delivery.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.